These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9291151)

  • 1. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease.
    Kodsi MH; Swerdlow NR
    Neurosci Lett; 1997 Aug; 231(2):103-7. PubMed ID: 9291151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E
    Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
    Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E
    Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat.
    Blum D; Gall D; Cuvelier L; Schiffmann SN
    Neuroreport; 2001 Jun; 12(8):1769-72. PubMed ID: 11409756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
    Sun Z; Xie J; Reiner A
    Exp Neurol; 2002 Jul; 176(1):55-65. PubMed ID: 12093082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
    Reynolds DS; Carter RJ; Morton AJ
    J Neurosci; 1998 Dec; 18(23):10116-27. PubMed ID: 9822765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
    Blum D; Gall D; Galas MC; d'Alcantara P; Bantubungi K; Schiffmann SN
    J Neurosci; 2002 Oct; 22(20):9122-33. PubMed ID: 12388620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.
    Brouillet E; Jacquard C; Bizat N; Blum D
    J Neurochem; 2005 Dec; 95(6):1521-40. PubMed ID: 16300642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.
    Borlongan CV; Koutouzis TK; Freeman TB; Cahill DW; Sanberg PR
    Brain Res; 1995 Oct; 697(1-2):254-7. PubMed ID: 8593585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parthenolide ameliorates 3-nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting.
    Noureldeen ME; Shahin NN; Amin HAA; El-Sawalhi MM; Ghaiad HR
    Mol Med; 2024 Sep; 30(1):158. PubMed ID: 39327568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid.
    Brouillet E; Jenkins BG; Hyman BT; Ferrante RJ; Kowall NW; Srivastava R; Roy DS; Rosen BR; Beal MF
    J Neurochem; 1993 Jan; 60(1):356-9. PubMed ID: 8417157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats.
    Shear DA; Haik KL; Dunbar GL
    Neuroreport; 2000 Jun; 11(9):1833-7. PubMed ID: 10884028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute systemic 3-nitropropionic acid administration on rat activity and acoustic startle.
    Seaman RL
    Neurosci Lett; 2000 Feb; 280(3):183-6. PubMed ID: 10675791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.
    Blum D; Galas MC; Pintor A; Brouillet E; Ledent C; Muller CE; Bantubungi K; Galluzzo M; Gall D; Cuvelier L; Rolland AS; Popoli P; Schiffmann SN
    J Neurosci; 2003 Jun; 23(12):5361-9. PubMed ID: 12832562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
    Beal MF; Brouillet E; Jenkins BG; Ferrante RJ; Kowall NW; Miller JM; Storey E; Srivastava R; Rosen BR; Hyman BT
    J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADIOL protects against 3-NP-induced neurotoxicity in rats: Possible impact of its anti-oxidant, anti-inflammatory and anti-apoptotic actions.
    Hanna DM; Tadros MG; Khalifa AE
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jul; 60():36-51. PubMed ID: 25689821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin.
    Saba J; López Couselo F; Turati J; Carniglia L; Durand D; de Laurentiis A; Lasaga M; Caruso C
    J Neuroinflammation; 2020 Oct; 17(1):290. PubMed ID: 33023623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
    J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid.
    Duan W; Guo Z; Mattson MP
    Exp Neurol; 2000 Sep; 165(1):1-11. PubMed ID: 10964480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.